Analytical Data
-
Gene name
LEFTY1
- Application
-
Alternative Names
LEFTY1；LEFTB；LEFTYB；Left-right determination factor 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O75610
-
Expression Region
77-366aa
-
AA Sequence
RFSQ SFREVAGRFL ALEASTHLLV FGMEQRLPPN SELVQAVLRL FQEPVPKAAL HRHGRLSPRS ARARVTVEWL RVRDDGSNRT SLIDSRLVSV HESGWKAFDV TEAVNFWQQL SRPRQPLLLQ VSVQREHLGP LASGAHKLVR FASQGAPAGL GEPQLELHTL DLGDYGAQGD CDPEAPMTEG TRCCRQEMYI DLQGMKWAEN WVLEPPGFLA YECVGTCRQP PEALAFKWPF LGPRQCIASE TDSLPMIVSI KEGGRTRPQV VSLPNMRVQK CSCASDGALV PRRLQP
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LEFTY1 (Left-right determination factor 1) is a member of the transforming growth factor-beta (TGF-β) superfamily and plays a crucial role in embryonic development, particularly in the establishment of left-right asymmetry in vertebrates. The study of LEFTY1 has gained significant attention due to its involvement in various developmental processes and its potential implications in disease mechanisms, such as cancer and congenital defects. Research has shown that LEFTY1 can inhibit nodal signaling, a pathway essential for the proper patterning of the embryonic axis. As such, LEFTY1 acts as a key regulator that maintains the balance in this signaling pathway during development. Moreover, aberrant expression of LEFTY1 has been linked to several types of tumors, highlighting its importance as a potential biomarker and therapeutic target. Investigations into LEFTY1 recombinant proteins provide valuable insights into its functional mechanisms, interactions with other signaling molecules, and its role in the modulation of cellular behaviors. Understanding LEFTY1's structure and function through recombinant technology can not only elucidate its contributions to normal developmental processes but also pave the way for novel therapeutic approaches in diseases where LEFTY1 is implicated. Thus, research into LEFTY1 recombinant proteins is essential for advancing our knowledge of developmental biology and could have significant clinical implications.
